Cumberland Pharmaceuticals Files 8-K Report

Ticker: CPIX · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1087294

Sentiment: neutral

Topics: filing, regulatory

Related Tickers: CPRX

TL;DR

CPRX filed an 8-K on 3/19/25, standard reporting stuff.

AI Summary

On March 19, 2025, Cumberland Pharmaceuticals Inc. filed an 8-K report. The filing indicates that the company is located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee, 37203, and can be reached at (615) 255-0068. This report is a current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing serves as an official notification to the SEC and the public about the company's current status and reporting obligations.

Risk Assessment

Risk Level: low — This is a routine filing that does not contain new material information about the company's financial performance or strategic direction.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing?

This 8-K filing is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, indicating a change or event that is of importance to investors.

When was this 8-K report filed?

The report was filed on March 19, 2025.

What is the principal executive office address for Cumberland Pharmaceuticals Inc.?

The principal executive offices are located at 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.

What is the company's telephone number?

The registrant's telephone number, including area code, is (615) 255-0068.

What is the Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc.?

The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding CUMBERLAND PHARMACEUTICALS INC (CPIX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing